Shuichi Shirane

661 total citations
35 papers, 375 citations indexed

About

Shuichi Shirane is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Shuichi Shirane has authored 35 papers receiving a total of 375 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Genetics, 19 papers in Hematology and 13 papers in Molecular Biology. Recurrent topics in Shuichi Shirane's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers), Acute Myeloid Leukemia Research (13 papers) and Kruppel-like factors research (12 papers). Shuichi Shirane is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers), Acute Myeloid Leukemia Research (13 papers) and Kruppel-like factors research (12 papers). Shuichi Shirane collaborates with scholars based in Japan, United States and Taiwan. Shuichi Shirane's co-authors include Norio Komatsu, Soji Morishita, Yoko Edahiro, Marito Araki, Akimichi Ohsaka, Yoshitaka Sunami, Yumi Hironaka, Yoshihisa Mizukami, Nami Masubuchi and Yinjie Yang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shuichi Shirane

26 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shuichi Shirane Japan 8 293 233 188 74 33 35 375
Jamie Wilhelm United States 6 85 0.3× 215 0.9× 162 0.9× 11 0.1× 44 1.3× 13 369
Magda Šišková Czechia 10 131 0.4× 344 1.5× 123 0.7× 12 0.2× 61 1.8× 22 395
Paweł Kuś Poland 4 80 0.3× 160 0.7× 58 0.3× 19 0.3× 79 2.4× 6 233
Marta Ubezio Italy 6 181 0.6× 234 1.0× 72 0.4× 15 0.2× 69 2.1× 10 325
Lourdes Hermosín Spain 7 91 0.3× 142 0.6× 81 0.4× 31 0.4× 9 0.3× 11 222
Heikki Hallman Finland 8 66 0.2× 126 0.5× 208 1.1× 16 0.2× 23 0.7× 9 344
S Miyawaki Japan 6 99 0.3× 216 0.9× 164 0.9× 72 1.0× 38 1.2× 8 338
Ulrich Pascheberg Germany 10 79 0.3× 211 0.9× 140 0.7× 25 0.3× 33 1.0× 12 327
Ryan J. Stubbins Canada 9 81 0.3× 102 0.4× 94 0.5× 85 1.1× 43 1.3× 26 286
Giulia Falconi Italy 13 124 0.4× 281 1.2× 189 1.0× 6 0.1× 34 1.0× 28 369

Countries citing papers authored by Shuichi Shirane

Since Specialization
Citations

This map shows the geographic impact of Shuichi Shirane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuichi Shirane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuichi Shirane more than expected).

Fields of papers citing papers by Shuichi Shirane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuichi Shirane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuichi Shirane. The network helps show where Shuichi Shirane may publish in the future.

Co-authorship network of co-authors of Shuichi Shirane

This figure shows the co-authorship network connecting the top 25 collaborators of Shuichi Shirane. A scholar is included among the top collaborators of Shuichi Shirane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuichi Shirane. Shuichi Shirane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shirane, Shuichi, et al.. (2025). Ropeginterferon-α2b discontinuation after long-term exposure: four cases from a single institution. International Journal of Hematology. 122(3). 458–461. 1 indexed citations
2.
Mukai, Masanori, et al.. (2025). Reversible Left Ventricular Dysfunction Related to Ropeginterferon Alfa-2b in Polycythemia Vera. International Heart Journal. 66(6). 1033–1035.
3.
Kirito, Keita, Yuka Sugimoto, Akihiko Gotoh, et al.. (2024). Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. International Journal of Hematology. 120(6). 675–683. 4 indexed citations
4.
Yasuda, Hajime, et al.. (2024). Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases. Frontiers in Immunology. 15. 1287300–1287300. 4 indexed citations
5.
Morishita, Soji, Yoshinori Hashimoto, Tomonori Ochiai, et al.. (2023). Impact of non‐driver gene mutations on thrombo‐haemorrhagic events in ET patients. British Journal of Haematology. 204(1). 221–228. 2 indexed citations
6.
Hashimoto, Yoshinori, Soji Morishita, Tomonori Ochiai, et al.. (2022). Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia. Journal of Thrombosis and Thrombolysis. 55(2). 263–272. 5 indexed citations
7.
8.
Hashimoto, Yoshinori, Hajime Yasuda, Marito Araki, et al.. (2022). Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan. Hematology. 27(1). 157–166. 4 indexed citations
9.
Edahiro, Yoko, et al.. (2021). Intravascular large B-cell lymphoma as a recurrence of primary central nervous system lymphoma after chemotherapy: A case report. SHILAP Revista de lepidopterología. 15. 100249–100249.
10.
Ando, Miki, Jun Ando, Midori Ishii, et al.. (2021). Trigenic ADH5/ALDH2/ADGRV1 mutations in myelodysplasia with Usher syndrome. Heliyon. 7(8). e07804–e07804. 3 indexed citations
11.
Shirane, Shuichi, Daisuke Watanabe, Noritaka Sekiya, Shinichiro Horiguchi, & Yuho Najima. (2021). Paraplegia via hematogenous dissemination of Cunninghamella elegans (mucormycosis) after hematopoietic stem cell transplantation. International Journal of Infectious Diseases. 113. 210–212. 2 indexed citations
12.
Takahashi, Yoshihiro, Taiji Tsunemi, Shuichi Shirane, et al.. (2020). Systemic Sclerosis Precedes POEMS Syndrome. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 48(3). 446–449.
13.
Yasuda, Hajime, Jun Ando, Masaaki Noguchi, et al.. (2019). Vitamin B6 deficiency is prevalent in primary and secondary myelofibrosis patients. International Journal of Hematology. 110(5). 543–549. 12 indexed citations
14.
Watanabe, Naoki, Tomoiku Takaku, Kazuyoshi Takeda, et al.. (2018). Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients. International Journal of Hematology. 108(6). 588–597. 8 indexed citations
15.
Yasuda, Hajime, Marito Araki, Tomonori Ochiai, et al.. (2018). Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms. International Journal of Hematology. 107(6). 673–680. 24 indexed citations
16.
Kaito, Satoshi, Yuho Najima, Tatsuya Konishi, et al.. (2017). Post-Transplant Maintenance Therapy with Azacitidine and Gemtuzumab Ozogamicin for High-Risk Hematologic Malignancies. Blood. 130. 4517–4517. 4 indexed citations
17.
Araki, Marito, Yinjie Yang, Nami Masubuchi, et al.. (2016). Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 127(10). 1307–1316. 194 indexed citations
18.
Sunami, Yoshitaka, et al.. (2015). Various Neurological Symptoms by Neurolymphomatosis as the Initial Presentation of Primary Testicular Lymphoma. Case Reports in Oncology. 8(1). 200–204. 5 indexed citations
19.
Edahiro, Yoko, Soji Morishita, Yumi Hironaka, et al.. (2014). JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. International Journal of Hematology. 99(5). 625–634. 24 indexed citations
20.
Shirane, Shuichi, Marito Araki, Soji Morishita, et al.. (2014). Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. International Journal of Hematology. 101(2). 148–153. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jamie Wilhelm Breakdown of academic impact, for papers by Magda Šišková Breakdown of academic impact, for papers by Paweł Kuś Breakdown of academic impact, for papers by Marta Ubezio Breakdown of academic impact, for papers by Lourdes Hermosín Breakdown of academic impact, for papers by Heikki Hallman Breakdown of academic impact, for papers by S Miyawaki Breakdown of academic impact, for papers by Ulrich Pascheberg Breakdown of academic impact, for papers by Ryan J. Stubbins Breakdown of academic impact, for papers by Giulia Falconi
Rankless by CCL
2026